Not registered yet? Please contact our project assistant Dennis Cleff . This area is only for members of the research consortium.


17. January 2024

DECISION project video

We are thrilled to announce the release of our latest video, which dives into the details of the DECISION project – a European research consortium, aiming to enhance our understanding of decompensated cirrhosis and acute-on-chronic liver failure at a systems level. 🎥

Join in, as project partners discuss their roles within the project and emphasise the importancesignificance of collaboration in advancing scientific research. Learn more about the upcoming clinical trial and the role and representation of patients within DECISION.

🔍 Watch the full video on YouTube:

More news


15 January 2024

Join discussions of DECISION experts

We are thrilled to invite industry stakeholders to be part of our research journey. You now have the opportunity to attend DECISION meetings, where experts of our research program discuss the latest advancements before they reach scientific publications.

By joining these discussions, you gain early access to cutting-edge research in the field of acute decompensation of cirrhosis and ACLF. We believe in collaboration and welcome your involvement.

In exchange for valuable insights, we are open to exploring customized solutions that align with your objectives. Your support will play a crucial role in advancing our research goals.

To secure your spot and discuss tailored opportunities, reach out to us at info[at]decision-for-liver[dot]eu.

Thank you for considering this collaboration. We look forward to welcoming you to our upcoming sessions.

More news


18 - 20 October, 2023

5th General Assembly Meeting in Padova, Italy

Members of the DECISION Consortium met in Padova, Italy, to discuss recent research results in preparation of several manuscripts shedding some new light on the pathophysiology of acute decompensation of cirrhosis and development of acute-on-chronic liver failure (ACLF) – a syndrome associated with high short-term mortality. After three years of intensive work, the upcoming COMBAT trial will use newly identified biomarkers to predict disease progression and test safety and effectiveness of a combinatorial drug therapy.

Originally published on the EF CLIF website.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more